Company news

Corvus Pharmaceuticals, Inc. news in 2024

Corvus Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

December 17, 2024

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

December 16, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

December 3, 2024

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

November 13, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

November 11, 2024

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

November 8, 2024

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

September 9, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

August 5, 2024

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

July 31, 2024

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 5, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

May 1, 2024

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

April 8, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 18, 2024

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

February 11, 2024

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

February 7, 2024

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

February 5, 2024

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

January 22, 2024

Calls in 2024